Current Report Filing (8-k)
September 01 2017 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Act of 1934
Date of Report (Date of earliest event reported):
August 30, 2017
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
40 Erie Street, Suite 130,
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (857) 285-6200
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13d-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the
Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.02(b).
|
Departure of Certain Officers.
|
On August 30, 2017, Nicole Heifner, Senior Vice President,
Accounting (and principal accounting officer) of Intellia Therapeutics, Inc. (the Company) informed the Company that she will be resigning from her position effective September 15, 2017 to pursue other employment opportunities.
Ms. Heifners resignation was not related to any disagreements with the Company on any matter relating to its operations, policies, practices or any issues regarding financial disclosures, accounting or legal matters.
Graeme Bell, Intellias Executive Vice President and Chief Financial Officer, will fulfill the duties of principal accounting officer until a permanent
successor is appointed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: September 1, 2017
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Nessan Bermingham
|
|
|
|
|
|
|
Nessan Bermingham, Ph.D.
|
|
|
|
|
|
|
President and Chief Executive Officer
|
2
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2023 to Sep 2024